WINT

WINT

USD

Windtree Therapeutics Inc. Common Stock

$0.618-0.031 (-4.780%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$0.648

الأعلى

$0.650

الأدنى

$0.600

الحجم

1.29M

أساسيات الشركة

القيمة السوقية

2.3M

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

4.53M

البورصة

NCM

العملة

USD

نطاق 52 أسبوعاً

الأدنى $0.52الحالي $0.618الأعلى $737.5

أخبار ذات صلة

GlobeNewswire

Windtree Receives Offer for Its Preclinical Oncology Drug Candidate

Company to receive $7.0 million up front for its preclinical oncology drug candidate Up to $130.0 million in milestone payments starting with initiation of Phase 1 High single digit royalties that could total up to

عرض المزيد
Windtree Receives Offer for Its Preclinical Oncology Drug Candidate
BusinessWire

Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc.

عرض المزيد
Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors
GlobeNewswire

Windtree Announces Plan for Cryptocurrency Treasury Policy

WARRINGTON, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing

عرض المزيد
Windtree Announces Plan for Cryptocurrency Treasury Policy
GlobeNewswire

Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

Istaroxime has previously completed two positive Phase 2 studies in SCAI Stage B cardiogenic shock; the SEISMiC C study in SCAI Stage C cardiogenic shock is another step progressing to the istaroxime cardiogenic shock

عرض المزيد
Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.